Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

691 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment algorithms in stage IV melanoma.
Espinosa E, Grob JJ, Dummer R, Rutkowski P, Robert C, Gogas H, Kefford R, Eggermont AM, Martin Algarra S, Hauschild A, Schadendorf D. Espinosa E, et al. Among authors: rutkowski p. Am J Ther. 2015 Jan-Feb;22(1):61-7. doi: 10.1097/MJT.0b013e31829e885c. Am J Ther. 2015. PMID: 24413374 Free article. Review.
Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes.
van Akkooi AC, Nowecki ZI, Voit C, Schäfer-Hesterberg G, Michej W, de Wilt JH, Rutkowski P, Verhoef C, Eggermont AM. van Akkooi AC, et al. Among authors: rutkowski p. Ann Surg. 2008 Dec;248(6):949-55. doi: 10.1097/SLA.0b013e31818fefe0. Ann Surg. 2008. PMID: 19092339
Surgery and radiotherapy in the treatment of cutaneous melanoma.
Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, Eggermont AM. Testori A, et al. Among authors: rutkowski p. Ann Oncol. 2009 Aug;20 Suppl 6(Suppl 6):vi22-9. doi: 10.1093/annonc/mdp257. Ann Oncol. 2009. PMID: 19617294 Free PMC article. Review.
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria.
van der Ploeg AP, van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, Newton-Bishop JA, Cook M, van der Ploeg IM, Nieweg OE, van den Hout MF, van Leeuwen PA, Voit CA, Cataldo F, Testori A, Robert C, Hoekstra HJ, Verhoef C, Spatz A, Eggermont AM. van der Ploeg AP, et al. Among authors: rutkowski p. J Clin Oncol. 2011 Jun 1;29(16):2206-14. doi: 10.1200/JCO.2010.31.6760. Epub 2011 Apr 25. J Clin Oncol. 2011. PMID: 21519012
Surgical management of melanoma: an EORTC Melanoma Group survey.
Testori A, Soteldo J, Powell B, Sales F, Borgognoni L, Rutkowski P, Lejeune F, van Leeuwen P, Eggermont A. Testori A, et al. Among authors: rutkowski p. Ecancermedicalscience. 2013 Mar 28;7:294. doi: 10.3332/ecancer.2013.294. Print 2013. Ecancermedicalscience. 2013. PMID: 23589724 Free PMC article.
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
Eggermont AM, Suciu S, Rutkowski P, Marsden J, Santinami M, Corrie P, Aamdal S, Ascierto PA, Patel PM, Kruit WH, Bastholt L, Borgognoni L, Bernengo MG, Davidson N, Polders L, Praet M, Spatz A. Eggermont AM, et al. Among authors: rutkowski p. J Clin Oncol. 2013 Oct 20;31(30):3831-7. doi: 10.1200/JCO.2012.47.9303. Epub 2013 Sep 9. J Clin Oncol. 2013. PMID: 24019551 Clinical Trial.
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.
Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter P, Mohr P, Trefzer U, Lefeuvre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu FS, Patel K, Casey M, Robert C. Schadendorf D, et al. Among authors: rutkowski p. Ann Oncol. 2014 Mar;25(3):700-706. doi: 10.1093/annonc/mdt580. Epub 2014 Feb 6. Ann Oncol. 2014. PMID: 24504441 Free PMC article. Clinical Trial.
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, Kämpgen E, Karaszewska B, Mauch C, Miller WH Jr, Millward M, Mirakhur B, Rutkowski P, Chiarion-Sileni V, Swann S, Hauschild A. Grob JJ, et al. Among authors: rutkowski p. Ann Oncol. 2014 Jul;25(7):1428-1436. doi: 10.1093/annonc/mdu154. Epub 2014 Apr 25. Ann Oncol. 2014. PMID: 24769640 Free article. Clinical Trial.
Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
Gos A, Jurkowska M, van Akkooi A, Robert C, Kosela-Paterczyk H, Koljenović S, Kamsukom N, Michej W, Jeziorski A, Pluta P, Verhoef C, Siedlecki JA, Eggermont AM, Rutkowski P. Gos A, et al. Among authors: rutkowski p. Ann Surg Oncol. 2014 Dec;21(13):4317-23. doi: 10.1245/s10434-014-3799-y. Epub 2014 May 28. Ann Surg Oncol. 2014. PMID: 24866436 Free PMC article.
691 results